NCT05118724View on ClinicalTrials.gov

Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

December 10, 2021

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Colorectal Cancer
Interventions
DRUG

Atezolizumab

Atezolizumab 840mg i.v., on Day 1 and Day 15 (q2w) of every 28-day treatment cycle for a total of 12 cycles (24 doses)

DRUG

IMM-101

Suspension of Heat-Killed Whole Cell Mycobacterium obuense (NCTC 13365) in Borate Buffered Saline for Intradermal Injection

Trial Locations (1)

45147

Westdeutsches Tumorzentrum, Essen

Sponsors
All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

collaborator

Immodulon Therapeutics Ltd

INDUSTRY

lead

AIO-Studien-gGmbH

OTHER

NCT05118724 - Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin | Biotech Hunter | Biotech Hunter